| Overview |
| bs-12066R |
| GABA A Receptor beta 2 + 3 Antibody |
| WB, ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), IP, ICC |
| Human, Rat |
| Mouse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human GABA A Receptor beta 2 + 3 |
| 301-400/512 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Cell membrane |
| GABA A receptor beta 3 subunit; GABA alpha receptor beta 2 subunit; GABAA receptor beta 2 subunit; GABAA receptor beta 3 subunit; GABAA receptor subunit beta 2; GABAA receptor subunit beta 3; GABRB2; GABRB3; Gamma Aminobutyric Acid A receptor beta 3; Gamma Aminobutyric Acid receptor beta 2 subunit; Gamma aminobutyric acid receptor subunit beta 2; Gamma aminobutyric acid receptor subunit beta 3; Testis gamma aminobutyric acid receptor subunit beta 3; GBRB2_HUMAN. |
| Gamma-aminobutyric acid type A (GABAA) receptors are members of the neurotransmitter ligand-gated ion channels that mediate neuronal inhibition on binding GABA. The effects of GABA on GABAA receptors are modulated by a range of therapeutically important drugs, including barbiturates, anaesthetics and benzodiazepines. |
| Application Dilution |
| WB |
1:300-5000 |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
| IP |
1-2ug |
| ICC |
1:100-500 |
Powered by Bioz